Compare British American Tobacco PLC (BTI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Sanofi SA — how do they compare? British American Tobacco PLC trades at $56.07 (market cap $122.36B), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: British American Tobacco PLC is the larger of the two by market cap, and British American Tobacco PLC pays the higher dividend (5.88%). Which is the better fit depends on your goals.
| BTI | SNY | |
|---|---|---|
Market Cap | $122.36B | $104.30B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $52.34 |
52-Week Low | $50.39 | $41.33 |
Enterprise Value | $166.31B | $124.19B |
Dividend Yield | 5.88% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $55.93, down 1.96% today, with a bearish technical signal and mixed earnings history. The company maintains strong profitability with an 83.56% gross margin and 24.99% net income margin, supported by a P/E of 14.48. Recent news highlights strategic tech partnerships and workforce restructuring to drive efficiency.
The outlook is cautious due to declining cash flow and regulatory risks, but the 5%+ dividend yield and analyst buy consensus (66.7%) offer value. Upside depends on successful transition to next-generation products, while core combustible declines and debt levels pose challenges.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
